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ABSTRACT
DOES THE METHOD OF TREATING BACTERIAL VAGINOSIS IN 
EARLY PREGNANCY AFFECT THE REOCCURRENCE RATE NEAR TERM?
By
Karen 5. Taylor 
There is no significant difference in the relationship 
between oral or vaginal metronidazole and oral clindamycin 
in the treatment of bacterial vaginosis (BV) in early 
pregnancy and the reoccurrence rate of BV at 35 to 37 weeks 
gestation. Treatment of BV in pregnancy has been shown to 
decrease the preterm delivery rate saving millions of 
dollars and improving the health of infants. This was a 
descriptive, correlational study using a retrospective 
chart review. A constructed checklist was used for 
collecting data from 18 6 charts.
Age, parity, and insurance were comparable in each of 
the three drug groups. The reoccurrence rate of BV when 
tested in the third trimester showed no significant 
differences in comparison of the three drug treatment 
groups (Chi-square = .55; df = 2; p = .76). All three 
drugs were equally effective in the treatment of BV.
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Chapter One 
INTRODUCTION
Preterm births continue to be the most significant 
pregnancy related problem in the United States.
Prematurity is responsible for almost 75% of neonatal 
mortality and as much as 50% of long term neurological 
damage in children (Hauth, Goldenberg, Andrews, DuBard, & 
Copper 1995). Reports have shown one-fifth of children 
weighing less than lOGOg at birth have moderate to severe 
neurosensory handicaps at 2 years of age (Novy, McGregor, & 
lams 1995). Handicaps can include blindness, deafness, 
mental retardation, epilepsy, and cerebral palsy. In 1990 
the costs for special education for 85,000 preterm children 
in the United States was $370 million (Novy et al.). As of 
1994, the United States ranked 22 out of 18 6 in world 
infant mortality rates. Many feel the poor ranking is due 
to the high number of premature births and low birth weight 
infants born here. Preterm birth rates remained relatively 
constant for 40 years until the 1980s. There has been a 
slow rise in rates especially in certain groups of women.
Nurse practitioners frequently make decisions on 
desired drug treatment given to obstetrical patients; 
therefore, they have the ability to have a positive 
influence on the preterm delivery rate. Prevention of
preterm deliveries is of utmost importance worldwide, 
because it not only will improve the health of many 
children but also will also save billions of dollars spent 
on their healthcare. Early identification and optimal 
treatment of bacterial vaginosis has the potential to 
decrease the incidence of preterm labor (Hack & Merkatz,
1995).
Why do preterm birth rates continue to rise despite 
hundreds of preventative interventions throughout the 
world? Programs such as early prenatal care, better 
nutrition, easier access to health care, increased social 
support, home uterine monitoring, increased education of 
patients and about tocolytic drugs have been shown to be 
unsuccessful in affecting the overall rate of preterm 
births (Goldenberg & Andrews, 1996). Therefore, 
researchers are focusing more on the reasons why preterm 
labor happens versus how to stop labor once it occurs. 
Numerous studies have shown that bacterial vaginosis (BV) 
has been a common link to labor before 37 weeks (Hillier et 
al. 1995). BV is one of the most common genital tract 
infections found in women. Up to 22% of pregnant women 
have this infection present at their initial examination 
(Hillier et al.). Chorioamnionitis is commonly caused by 
BV and is found in up to 80% of deliveries prior to 30
weeks gestation (Goldenberg & Andrews).
Bacterial vaginosis is an overgrowth of normal 
vaginal organisms. It begins in the lower genital tract 
and often ascends through the cervix to the uterus 
affecting the pregnancy. Even after adjustment for 
variables such as previous preterm delivery or maternal 
weight below 110 lbs, women with BV are 40% more likely to 
give birth before term (Hillier et al, 1995). One study in 
Indonesia showed the rates of preterm delivery were almost 
doubled for those diagnosed with BV in the early second 
trimester (20.5%) as compared with those diagnosed in late 
pregnancy (10.7%) (Riduan et al. 1993).
Antimicrobial therapy given to pregnant women positive 
for BV in the second trimester decreases the risk of 
preterm delivery (Hauth et al. 1995). Currently there are 
four primary antibiotic treatments used. Metronidazole has 
always been the drug of choice for treatment of BV in the 
non-pregnant woman. Many practitioners are reluctant to 
use metronidazole in the pregnant patient because of the 
possible mutagenic and/or carcinogenic effects in the 
infant, especially in the first trimester. A  recent meta­
analysis does not show teratogenicity in humans (Centers 
for Disease Control and Prevention, 1998). Centers for 
Disease Control (CDC) treatment guidelines for 1998
continue to recommend oral metronidazole as the drug of 
choice in the treatment of BV. Other drug choices include 
oral clindamycin, metronidazole vaginal gel 0.75%, and 
clindamycin 2% vaginal cream. CDC guidelines no longer 
recommend clindamycin vaginal cream during pregnancy due to 
recent studies indicating an increase in the rate of 
preterm births with its use.
Much discussion has taken place on which drug 
treatment is the most effective in eradicating the 
infection. Once the microorganisms ascend the upper 
reproductive tract, intravaginal medications may not be 
helpful to prevent preterm deliveries. Thus, the CDC 
(1998) no longer recommends intravaginal treatments for 
pregnant women who have previously delivered a premature 
infant. Studies vary slightly on the effectiveness rates 
of the above mentioned antibiotics. Joesoef and Schmid 
(1995) found no significant difference in efficacy between 
oral metronidazole and oral clindamycin (96% vs 94%).
Ferris, Litaker, Woodward, Mathis, and Hendrich (1995) 
reported similar findings. Some clinicians are hesitant to 
use clindamycin due to possible gastrointestinal problems 
including pseudomembranous colitis (occurrence rate 2% to 
10%) (Reynolds, 1991) . Recommended doses for the treatment 
of BV in pregnancy are well within dosage guidelines. Due
to the fact that many clinical practices may not reevaluate 
the patient unless symptomatic, the most effective drug 
should be used if possible in order to increase the patient 
cure rate. Many times nurse practitioners are the primary 
providers for identification and treatment of bacterial 
vaginosis. Nurse practitioners may not only save lives of 
infants born too early, but also save millions of dollars 
through decreased hospitalizations and long term care.
The purpose of this study was to examine differences 
in the relationship between oral metronidazole, vaginal 
metronidazole or oral clindamycin treatment of BV in early 
pregnancy (before 16 weeks) and the recurrence rate of BV 
at 35 to 37 weeks gestation.
Chapter Two 
CONCEPTUAL FRAMEWORK 
The conceptual framework for examining the 
relationship between treatment method for BV in early 
pregnancy and the recurrence rate near term will be based 
on the Betty Neuman Health Care Systems Model (Neuman/
1989). Neuman began developing her theory in the late 
1960s in response to requests from graduate students 
(Beckman,- 1994) . Her completed conceptual model was 
presented in 1970 and has been further developed several 
times since then (Beckman). The model is a product of her 
philosophy and observations made in teaching mental health 
nursing and in counseling (Neuman).
Neuman labels her systems theory as a general theory 
involving an open system approach. Neuman's systems model 
incorporates stress as the deciding factor for all 
interventions for the self or environment. Neuman (1993) 
believes a person's health centers around stressors and 
coping. Inability to cope results in illness and sometimes 
death. The self is in constant interaction with the 
environment. The goal of the intervention is to strengthen 
the basic structure (the self) so that the effect of the 
stressor is minimized (Bullock, 1993).
Neuman's model contains several circles or rings
around the self(See Figure 1). The rings differ for each 
person because they include information from physiologic, 
psychologic, sociocultural, developmental, and spiritual 
attributes (Bullock, 1993). The outermost ring is the 
flexible line of defense. It expands to provide increased 
protection and contracts for less protection of the self or 
core. The flexible line of defense represents the 
immediate responses an individual makes to actual or 
potential stressors. Distance of the stressors from the 
core varies according to the needs and abilities of the 
client. Stressors vary with age, health status, 
educability and resources. The next inner ring is the 
normal line of defense. This represents a stability state, 
baseline or standard, which develops over time.
The innermost circles are called the lines of 
resistance and are the body's attempt to stabilize against 
the disequilibrium caused by the stressor (Bullock, 1993). 
The lines of resistance include those things an individual 
does at a conscious or subconscious level to restore 
equilibrium or achieve an even higher level of stability. 
The lines of resistance include prevention at primary, 
secondary, and tertiary levels. Educating a woman on how 
to reduce her risk factors for BV (e.g. frequent partners, 
smoking, and douching) is an example of primary
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Figure 1. Neuman's Systems Model 
Neuman (198 9)
prevention. Secondary prevention involves interventions or 
treatments initiated after symptoms have occurred. This 
would include antibiotic treatment of BV. Tertiary 
intervention occurs after actual treatment. The goal of 
tertiary intervention is reconstitution of the woman to an 
optimal level of health (Bullock, 1993). Exploring ways to 
decrease the recurrence of BV would be an example of 
tertiary intervention. It focuses on readjustment toward 
optimal stability.
The inner most ring is the core. The core is 
represented by a solid line to indicate its stability. The 
core consists of those things necessary for survival such 
as temperature and organ function. The person's individual 
genetic makeup, such as weaknesses and strengths of 
different body parts, ego, and response patterns also 
affect the core. The core may also represent a family, 
group or community. Penetration of the core could lead to 
death or destruction. Strengthening the lines of defense 
and the lines of resistance helps to protect the core.
In summary, Neumans Systems Model (198 9) is a holistic 
model which addresses the social, developmental, 
psychological, physical, and spiritual aspects of the 
pregnant woman and how they are impacted by stressors. The 
rings of resistance protect the inner core of the woman and
her pregnancy. Bacterial vaginosis may weaken the flexible 
line of defense leading to pelvic infections, premature 
rupture of membranes or preterm labor. Treating the 
pregnant patient with the most effective antibiotic will 
help her to strengthen her lines of resistance and 
reestablish her normal line of defense.
Review of Literature
The vaginal ecosystem is the normal line of defense. 
Lactobacilli, a Gram positive bacilli, dominate other 
vaginal microorganisms to maintain a healthy genital tract 
through maintenance of pH and generation of antimicrobial 
hydrogen peroxide (Overman, 1993). Eschenbach and Mead 
(1992) reported that 96% of normal women were found to have 
peroxide-producing lactobacilli. Vaginosis is an imbalance 
of this ecosystem associated with decreased numbers of 
lactobacilli and increased Gram-negative organisms. The 
normal vaginal ecosystem may be influenced by the menstrual 
cycle, pregnancy, menopause, contraceptive methods, 
douching, use of antibiotics, disease, stress, frequent 
intercourse, and trauma.
Lactobacilli control the lower genital tract by two 
mechanisms, primarily by producing a by-product called 
lactic acid. It is thought that conversion of glycogen 
from vaginal epithelial cells creates lactic acid (Overman,
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1993). Lactic acid produces an optimal acidic environment 
that limits the growth of microorganisms rec[uiring an 
alkaline environment to survive. The second feature is the 
production of hydrogen peroxide by the lactobacilli. 
Peroxidases are found in white blood cells, mucus, and 
vaginal secretions, and halides are found in cervical mucus 
(Overman, 1993) . Hydrogen peroxide, peroxidase, and 
halide are normally present in the healthy female genital 
tract. Together they create a environment toxic to many 
potential pathogens.
According to Reynolds (1991), Gardner and Dukes were 
first to identify bacterial vaginosis in 1955. Initially 
it was called Haemophilus vaginalis due to its appearance 
like the Haemophilus genus. Until this time, clinicians 
called the infection "nonspecific vaginitis". Over the 
years, it has assumed several other names as more 
information unfolded as to the particulars of the infection 
and criteria for diagnosis. When the organism resembled 
the genus Corynehacterlum rather than Haemophilus, the name 
changed to Corynehacterlum vaginalis (Reynolds) . Anaerobic 
vaginitis was another descriptive name given due to the 
high levels of Gram-negative anaerobes (Ament & Whalen,
1996) . Probably the most recognized name is Gardnerella 
vaginalis (named for its discoverer, Gardner) . The current
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term is bacterial vaginosis or BV.
All the organisms associated with bacterial vaginosis 
are found normally in the vagina. In women with BV, the 
normal vaginal ecosystem is altered from one with high 
concentrations of hydrogen peroxide producing lactobacilli 
to one with high concentrations of Gram-negative anaerobes 
and other bacteria (Freeman, 1995). These bacteria can 
increase 100 to 1000 fold over what they would be normally 
(Hillier, 1995). Bacteria can include Bacteroides species, 
Mobiluncus species, Gardnerella vaginalis, and Mycoplasma 
homlnls. Anaerobes produce amines such as putrescine and 
cadaverine which raise the pH to an alkaline level, 
promoting overgrowth and causing an unpleasant odor 
(Handsfield, 1992).
Bacterial vaginosis is a noninflammatory response to 
the change in the vaginal ecosystem. Women will quite 
frequently have no symptoms of infection. Reported 
symptoms can include frothy, watery, milky gray or yellow 
homogenous discharge. Often, a characteristic foul fishy 
odor is present also (Moore & Freda, 1998).
Diagnosis of BV can usually be made with microscopic 
examination of vaginal secretions during a clinical visit. 
The test is easy, inexpensive, and accurate. Two slides 
are prepared with one drop of vaginal discharge on each.
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Each slide is examined at lOX and 40X. The first sample is 
mixed with normal saline. In BV, clue cells, coccobacilli 
adhering to squamous epithelial cells, give them a 
peppered" appearance. Lactobacillus, normally visible in 
abundant numbers, are greatly reduced or absent. A drop of 
10% potassium hydroxide (KOH) is added to the second slide. 
Potassium hydroxide volatilizes the amines, putrescine, and 
cadaverine giving off a fishy, ammonia-like odor. These 
same amines are found in rotting fish. This odor is 
present in 90% of BV infections (Eschenbach & Mead, 1992).
Due to the likelihood of an alkaline environment with 
BV, pH should also be done to confirm the diagnosis. 
Bacterial vaginosis generally has a pH greater than 4.5. 
Normal vaginal pH is between 3.0 and 4.0. Gram staining is 
another option if the diagnosis is inconclusive. Vaginal 
secretions are rolled onto a glass slide and heat fixed or 
air dried. The smear is then stained with Gram stain by 
the usual Gram stain procedure. Bacteria that remain 
purple are Gram positive and those which stain red are Gram 
negative. Vaginal cultures, although more expensive, can 
also be done.
The origins of bacterial vaginosis are not well 
understood. Although there is an increased incidence in 
women with multiple sex partners, it is not considered to
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be sexually transmitted. Young girls and virginal women 
have been diagnosed with BV. Other risk factors may 
include low socioeconomic status, frequent douching, 
increased parity, smoking, young age. Black race, frequent 
intercourse, and condom use (Morales et al, 1994) . A study 
in Milwaukee reported 33% of pregnant adolescents tested 
positive for BV (Ament & Whalen, 1996). Hauth and 
coworkers (1995) reported that Black women had nearly three 
times as much BV as white women. The use of intrauterine 
devices also increases the risk of infection.
'‘How does Gaxdernella vaginalis get into the uterus 
during pregnancy?" Two theories are suggested. The first 
explanation is that the bacteria are already present in the 
uterus prior to pregnancy. This colonization often causes 
an asymptomatic endometritis. The infection remains low 
key until the membranes adhere to the decidual lining of 
the uterus at about 20 weeks gestation, sealing the uterus 
closed (Goldenberg & Andrews, 1996). The second theory is 
that lower genital tract bacteria ascend through the 
cervical canal to the uterus. Novy et al.(1995) stated that 
organisms associated with BV have been recovered from the 
amniotic fluid in 5-20% of women in preterm labor with 
intact membranes.
Elevated by-products of BV such as vaginal or cervical
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endotoxin, lancinase, sialidase, and interleukin-Al are 
thought to produce inflaimaatory cytokines (Hillier et al. 
1995). Arachidonic acid metabolites called eicosanoids are 
also produced (Novy et al. 1995). Eicosanoids are involved 
in the biosynthesis of prostaglandins and leukotrienes. 
Women with cervical dilation and amnionic infection have 
higher levels of cytokines and prostaglandins (Novy et 
al.). The role of prostaglandins in cervical dilatation 
and effacement has been well documented (Reynolds, 1991) .
It has been suggested that inflammatory cells produce 
proteases which may overpower mucous membranes and weaken 
the connective tissue strength of the chorioamnion and 
cervix (Novy et al.) . The connective tissue is an example 
of the flexible line of defense. The weakened state can 
lead to premature rupture of placental membranes or 
cervical dilatation.
Metronidazole has been the drug of choice for the 
treatment of BV since the 1980s. It is a member of the 
imidazole class of antibacterial drugs. Metronidazole is 
believed to reduce its nitro group under anaerobic 
conditions which leads to cytotoxic products that interfere 
with the DNA and kill the bacteria (Murphy & Jones, 1994) . 
More than half of the drug is broken down in the liver.
This breakdown produces metabolites that also kill
15
bacteria. Lactobacilli are not affected by the drug, which 
allows the vaginal ecosystem to return to normal. Peak 
serum levels of 20-25 ug/ml are achieved in one to three 
hours unless taken with a meal (Peppercorn, Shelley, & 
Sobel, 1993). Serum half-life varies from 6 to 12 
hours. Metronidazole passes through the placenta and can 
be found in fetal tissue and amniotic fluid (Murphy & 
Jones). It is also found in breast milk in concentrations 
equal to serum levels (Murphy & Jones). Side effects may 
include gastrointestinal upset, nausea, metallic taste, 
vaginal burning, sleeplessness, headache and ataxia. 
Metronidazole should not be used concomitantly with 
disulfiram (Antabuse) which can cause respiratory 
depression, cardiovascular collapse, arrhythmias, 
myocardial infarction, acute heart failure, seizures, 
unconsciousness, or death.
Many clinicians are reluctant to use metronidazole 
during pregnancy due to q[uestions regarding possible 
carcinogenic and teratogenic effects. Metronidazole was 
shown to be nonteratogenic in rats, mice, and guinea pigs 
and carcinogenicity has never been reported in humans 
(Burtin, Taddio, Ariburnu, Einarson, & Gideon, 1995). A 
meta-analysis performed by Burtin et al. (1995) reported 
that the use of metronidazole in pregnant women does not
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appear to increase teratogenicity. Burtin et al. reviewed 
all medical literature published on metronidazole use 
during pregnancy since its release in 1959. Thirty-two 
articles were found that reported original data. Oral 
metronidazole or a combination of oral and vaginal 
metronidazole was used for treatment courses lasting 7 to 
10 days. Comparisons were made between treatment in the 
first trimester and treatment during the third trimester 
when dysmorphologic development cannot occur (Burtin et 
al.) Three criteria were developed to be included in the 
meta-analysis: (1) at least 10 women exposed to
metronidazole during the first trimester of pregnancy; (2) 
at least 10 women not exposed to metronidazole or only 
during the third trimester; (3) all malformations observed 
in live-born infants reported in each group (Burtin et 
al.). Seven out of the 32 studies met all three criteria 
for meta-analysis. Studies ranged from 13 to over 1000 
exposed women. None of the odds ratios detected a 
significantly increased risk of birth defects among infants 
with exposure to metronidazole in the first trimester. The 
overall odds ratio of exposure versus no exposure during 
the first trimester was 0.93. There was no increased 
teratogenic risk found (Burtin et al.) The Centers for 
Disease Control (CDC) and Prevention agrees with these
17
meta-analysis findings (1998). Metronidazole is the 
preferred drug of choice in the treatment of BV in 
pregnancy according to the CDC. Metronidazole eradicates 
anaerobes through the activity of its hydroxy metabolite.
McDonald, O'^ Loughlin, Vigneswaran, Jolley, and 
McDonald (1994) conducted a randomized, double-blind, 
placebo controlled study of metronidazole treatment in 
pregnant women with BV. Diagnosis was made with the use of 
direct smears and low vaginal vault cultures. The 
antenatal clinic screened 2606 women for BV at 16-24 weeks 
gestation. Twenty-eight percent (739) tested positive for 
BV. Due to exclusions such as refused consent, age less 
than 17, antibiotic therapy for vaginal discharge in the 
preceding 2 weeks, allergy to metronidazole, placenta 
previa with bleeding, premature rupture of membranes, 
multiple gestation, and diabetes, the final sample size was 
135 women. Sixty-six with BV were treated with medication 
and 69 were in the control (placebo) group.
Chi-square with Yates correction was used to test the 
differences between the metronidazole group (n=66) and the 
control placebo group (n=69). McDonald et al. (1994) also 
calculated the odds ratio and 95% confidence intervals. 
Sequential allocation from a list of random numbers, in 
blocks of 16 was used for randomization to the control the
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and experimental group. Metronidazole effectively 
suppressed BV in 43% of pregnant women compared with 25% in 
the placebo group (p<.05) . The odds ratio was 0.12 and the 
confidence interval was 0.03-0.4 (McDonald et al.)
Hauth et al. (1995) found similar results in their 
research. Over 5000 pregnant women were screened to 
participate and a total of 624 were enrolled. Both groups 
of women had similar characteristics such as weight, 
parity, compliance, age, weeks of gestation, and Black 
race. Of the 624 participants, 433 received metronidazole 
and 191 received the placebo. A blocked randomization 
schedule in a ratio of 2:1 was used (two women treated with 
metronidazole for every one woman assigned to a placebo). 
Similar diagnostic tests used by McDonald et al. (1994) 
were performed to confirm BV. The same tests were repeated 
two to four weeks after treatment was completed. T-test, 
chi-square, and Fisher's exact tests were used to analyze 
the data. Follow-up cultures on the group treated with 
metronidazole showed a 25.6% decreased incidence of BV. 
Initially, 40.7% had BV whereas 15.1% had BV post treatment 
(p <.001). The placebo group only had a 2% decrease. 
Initially, 45.6% had BV and 43.6% tested positive after 
treatment (p .71).
Morales, Schorr, and Albritton's (1994) research
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supports the previous study. Research methods and 
diagnosis of BV were similar. Eighty pregnant women were 
enrolled in a double-blind study. Forty-four women were 
treated with 250 mg of metronidazole orally, three times 
daily, for seven days; and 36 women were given a placebo. 
Demographic variables were comparable between the treatment 
and the control group. This study did not re-culture the 
pregnant women. It compared the number of hospital 
admissions for preterm labor, gestational age at delivery, 
birth weight, and premature rupture of membranes.
Data were analyzed with t tests and Chi-square tests. 
Hospital admissions, low birth weight, and premature 
rupture of membranes were shown to be statistically 
significant with a p<. 05. Admissions for the metronidazole 
group were 27% vs 78% for the placebo group. Birth weight 
less than 2500 g was 14% for the metronidazole-treated 
group vs 33% for the placebo group. Premature rupture of 
membranes occurred in 5% of the metronidazole group vs 33% 
in the placebo group.
Clindamycin is also effective against anaerobic 
bacteria associated with BV and is not contraindicated in 
the first trimester. Clindamycin is a semisynthetic 
antibiotic produced by a 7(S)-chloro-substitution of the 
7®—hydroxyl group of the parent compound lincomycin. It is
20
excreted by the liver and kidneys.
McGregor et al. (1995) conducted a prospective, 
controlled trial on the use of oral clindamycin in pregnant 
women. The study included 1138 pregnant women who were 
divided into two groups. The first group (559) was 
enrolled at the initial prenatal visit before 22 weeks 
gestation. The second group (579) was followed beginning 
between 22 and 29 weeks. BV was diagnosed in 30.9% of the 
women in group 1 and 33.6% in group 2 (p=.4) McGregor et 
al. Variables such as maternal age, ethnic background, 
marital status, parity, diabetes, and antenatal bleeding 
were similar for both groups. Diagnosis was made through 
microscopic examination and vaginal cultures. Oral 
clindamycin, 300 mg, twice daily was given to women testing 
positive for infection. Test of cure cultures were done 
between 22 and 29 weeks gestation.
Descriptive statistics and logistic regression were 
used to examine the effects of the risk factors. Women in 
both groups treated with oral clindamycin showed a cure 
rate of 92.5% at the 2 to 4 week follow-up visit (McGregor 
et al. 1995). Treating BV in the second trimester reduced 
the risk of premature labor to 25%. A  woman with BV and a 
prior preterm delivery has a risk of premature delivery of 
46.2%; p=.l, relative risk 0.54, 95% confidence interval
21
0-2 to 1.3).
The Centers for Disease Control released treatment 
guidelines for bacterial vaginosis in January,^ 1998. 
Recommendations include screening and treating high risk 
pregnant women early in the second trimester. High risk 
women are those who have delivered premature infants. Low 
risk women do not need to be screened unless they are 
symptomatic. Centers for Disease Control (1998) treatment 
guidelines for high risk pregnant women are as follows :
Recommended: Metronidazole 250 mg orally, three times
a day for 7 days
Alternative: (1) Metronidazole 2 grams orally, in a
single dose or (2) Clindamycin 300 mg orally, twice 
daily for 7 days
Treatment guidelines for low risk pregnant women are as 
follows: Recommended: Metronidazole 250 mg orally,
three times a day for 7 days
Alternative: (1) Metronidazole 2 grams orally,
in a single dose or 2) Clindamycin 300 mg orally, 
twice a day for 7 days or (3) Metronidazole gel,
0.75%, one full applicator (5g) intravaginally 
twice a day for 5 days (pp. 70-74)
Metronidazole doses have been lowered from the previous 
500 mg dose to limit drug exposure to the fetus. Also, the
22
use of clindamycin vaginal cream in pregnancy is no longer 
recommended due to the possible link with increased preterm 
deliveries.
Summary and Implications for Study 
Numerous research studies have shown that BV increases 
the incidence of premature rupture of membranes and preterm 
labor. Treatment of BV with oral metronidazole, vaginal 
metronidazole, or oral clindamycin greatly reduces the 
percentage of ruptured membranes and/or preterm labor. 
Limitations of the previous studies include no comparison 
of metronidazole vs clindamycin nor comparison of oral vs 
vaginal route in the pregnant patient; therefore, it is not 
known which drug and method of administration is most 
beneficial to the pregnant woman.
Research Question 
The purpose of this study was to examine the 
relationship between the type of drug treatment of 
bacterial vaginosis (oral metronidazole, vaginal 
metronidazole, or oral clindamycin) in pregnancy in females 
ages 12 to 43 years old before 16 weeks gestation and the 
recurrence rate between 35 and 37 weeks, using a 
retrospective chart review. The goal was to discover if 
there were a difference in recurrence rates as reported in 
the charts at 35 to 37 weeks gestation among pregnant women
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treated with either of the three treatment regimens. 
Vaginal clindamycin will not be included in the study 
because the Centers for Disease Control recommended 
discontinuing its use in pregnancy (Mead & Eschenbach,
1998) . Variables in the study will be the three types of 
medication (oral metronidazole, vaginal metronidazole, and 
oral clindamycin) and recurrence rates.
The answer would not only be helpful for health care 
providers treating BV in pregnancy but would also benefit 
the patient and fetus. Using the most successful drug 
could possibly eliminate years of health problems for a 
neonate born prematurely.
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Chapter Three 
METHODS 
Research Design 
This was a descriptive, correlational study using a 
chart review to examine the relationship between 
metronidazole (oral or vaginal) or oral clindamycin 
treatment of BV in early pregnancy (before 16 weeks) and 
the recurrence rate of BV at 35 to 37 weeks gestation.
A checklist developed by the investigator was used for 
collecting data from the patientas chart- Problems of 
response biases are greatly reduced when obtaining data 
from existing records (Polit & Bungler, 1993). One 
limitation of this type of data collection is that of 
assuming all information was assessed and entered correctly 
into the chart.
A retrospective chart review was used to obtain needed 
data. Retrospective studies look at events that have 
already occurred and try to determine what variables 
contributed to the effect (Talbot, 1995). An advantage is 
that existing data in the patients chart may be used.
Sample and Setting 
Information and data were collected from completed 
patient charts in an obstetric and gynecology office.
Prior written approval to review all charts was obtained
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from the office manager (Appendix A) . The office is 
located in a mid western state and currently employs two 
physicians and five certified nurse midwives. All 
providers care for pregnant women. The population consists 
mostly of Caucasians; however. Black, Hispanic, and Indian 
women are also in this setting. Payer mix is about 50% 
private insurance and 50% public assistance.
Data collection was done after office hours and on 
weekends. This provided easier access to patient 
information and did not interfere with patient flow. No 
charts were removed from the office. Patient names or 
identification were not collected to maintain 
confidentially. Approval for this study was obtained from 
the Human Research Review Committee of Grand Valley State 
University (Appendix B).
All patient charts in the office were audited to 
identify the pregnant patients. Charts from 1532 patients 
pregnant in 1996, 1997 and 1998 were reviewed for the 
appropriate information. It was estimated that 
approximately 4-6 charts could have been omitted if locked 
in a providers private office although this was against 
office policy. Patients included in this study were those 
testing positive for bacterial vaginosis on a routine 
culture before 16 weeks gestation who then had a routine
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culture between 35 and 37 weeks gestation (N=186). 
Exclusion criteria included diagnosis of vaginal group B 
beta strepcocci(GBS) infection prior to current 
pregnancy(not re-cultured routinely at 35 to 37 weeks), 
delivery before 37 weeks, and identification and treatment 
of BV between 16 weeks and 35 weeks with current pregnancy. 
Patients excluded for the above reasons do not have the 
routine vaginal culture performed between 35 and 37 weeks. 
Treatment with oral metronidazole, vaginal metronidazole, 
or oral clindamycin was also a requirement for inclusion. 
All providers use all drugs listed. All providers used the 
same laboratory facilities and diagnostic standards.
Instruments
A check list developed by the researcher was used 
(Appendix C). Checklist categories included: patient 
number, gestation at first culture, gestation at second 
culture, culture results before 16 weeks, culture results 
between 35 and 37 weeks, oral metronidazole use, vaginal 
metronidazole use, oral clindamycin use, BV recurrence 
before 35 weeks, and delivery before 37 weeks. Demographic 
patient information available in the chart such as parity, 
age, and insurance status were also collected. Each chart 
was identified with an assigned number.
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Chapter 4 
RESULTS
This descriptive, correlational study used a chart 
review to examine the relationship between metronidazole 
(oral or vaginal) or oral clindamycin treatment of BV in 
early pregnancy. Statistical analyses were done using SAS 
statistical software to provide statistics. Statistical 
analysis was performed through chi-square which is used to 
assess differences between two or more nominal-level 
variables (Polit & Hungler, 1993). Differences were 
considered significant at p<.05. Of the 1532 charts 
reviewed, 271 pregnant women tested positive for BV. 
Eight-five women were eliminated for the following reasons : 
initial culture performed after 16 weeks gestation, no drug 
treatment given with initial diagnosis, different drug 
treatment used, positive diagnosis of GBS with previous or 
current pregnancy, preterm delivery, and recurrence of BV 
before 35 to 37 weeks gestation. After review of the 
criteria, 18 6 women were included in the study: 70 (37.6%) 
treated with oral metronidazole, 56 (30.1%) treated with 
vaginal metronidazole, and 60 (32.3%) treated with oral 
clindamycin. The three drug treatment groups did not 
differ significantly with regard to age, parity, and 
insurance, as summarized in Table 1. The mean age of women
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was 23.9 (standard deviation [SD]=5.48) years with a range 
of 12 to 43 years. Mean parity was 2.2 (SD=1.17) with a 
range of 1 to 6. Seventy percent of the study group 
received medicaid public assistance.
Table 1. Comparison by drug group of women
Drug
Me txon±da.zole 
oral (d~70)
Metronidazole 
vaginal (n=56)
Clindamycin 
oral (n=SO) ■ Significance
Age (yrs) Mean 23.8 
SD 6.3
Mean 24 
SD 5.4
Mean 23.9 
SD 4.3
MS
Parity Mean 2.2 
SD 1
Mean 2.3 
SD 1.3
Mean 2.1 
SD 1.7
NS
Medicaid 51 41 39 NS
Private
Insurance
19 15 21 NS
Table two compares age, parity, and insurance in women 
who had recurrence of BV between 35 and 37 weeks gestation. 
Findings were similar to those reported in table one and 
were not significant.
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Table 2. Women with positive BV cultures
Initial
Group
Final 
Group •
Significance
Age (yrs) Mean 23.9 
SD 5.48
Mean 22.3 
SD 5.24
NS
Parity Mean 2.2 
SD 1.17
Mean 1.8 
SD .71
NS
Medicaid 70 73 NS
PI 30 27 NS
NS = not significant; SD = Standard deviation;
PI = private insurance
The recurrence rates for bacterial vaginosis between 35 
and 37 weeks gestation were 20% for oral metronidazole, 18% 
for vaginal metronidazole, and 15% for oral clindamycin.
As shown in Table 3, there was no statistically significant 
difference in recurrence rates of BV at 35 to 37 weeks 
gestation among pregnant women in the three treatment 
groups.
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Table 3. Culture results at 35 to 37 weeks gestation
Positive. Negative
Metronidazole- 14 (20%) 56 (80%)
Vaginal Metronidazole 10 (18%) 46 (82%)
Oral Clindamycin 9 (15%) 51 (85%)
Chi-square = .55; df =2; p = .76
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Chapter 5 
DISCUSSION AND IMPLICATIONS 
Discussion
This was a study done to examine the relationship 
between oral metronidazole^ vaginal metronidazole, or oral 
clindamycin treatment of BV in early pregnancy and the 
recurrence rate near term. Age, parity, and insurance type 
were comparable in each of the three drug groups. All 
women in the three test groups were cultured vaginally 
before 16 weeks gestation and between 35 and 37 weeks 
gestation. There were 18 6 women who met the review 
criteria to be included in this study.
The recurrence rate of BV when tested between 35 and 
37 weeks gestation showed no differences when comparing the 
three drug treatment groups. Twenty percent of the oral 
metronidazole group tested positive for BV while the 
vaginal metronidazole group had 18% and oral clindamycin 
had 15%. Therefore, there was no relationship between the 
use of oral metronidazole, vaginal metronidazole, and oral 
clindamycin in the treatment of BV in early pregnancy 
(before 16 weeks) and the recurrence rate of BV at 35 to 37 
weeks gestation. There were no studies found that compared 
the three drugs used but the findings were comparable to 
the research studies done by McDonald et al. (1994),
Morales, Schorr, and Albritton (1994), and McGregor et al. 
(1995) as mentioned in chapter two. This study was built
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on the previous author's research comparing any two of the 
drugs mentioned.
Liioitations
Retrospective chart reviews help to control bias and 
increase validity due to the fact that information 
collection occurs afterward. One limitation to this type 
of study is the assumption that all information was entered 
correctly into the medical record. Making the assumption 
that the patient completed the drug treatment as directed 
is another limitation. The time frame between vaginal 
cultures was approximately 20 to 25 weeks. Due to this 
extended period of time, it would be difficult to determine 
if the positive BV results at 35 to 37 weeks were due to 
continuance of the same infection or an acquired new 
infection of BV. Comparison to findings in other research 
studies was difficult due to the inability to find studies 
with similar interests and variables. And, because of the 
small sample size, this study may not have sufficient power 
to detect different recurrence rates among the three 
treatment regimens. Data stating what drug was used in the 
treatment of BV in patient's who delivered before 35 weeks 
gestation would have been helpful.
Efforts to control internal validity were as follows : 
the same two laboratories were used; all patients were 
cultured at first visit (before 16 weeks); charts were 
reviewed by one person; the same criteria were used to
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determine diagnosis of BV; and, all three groups were 
evaluated by the same personnel in the same office setting. 
Bias was decreased because all pregnant women meeting the 
criteria were included in the study. A  limitation to 
external validity was that there was no control over high- 
risk behaviors such as frequent intercourse, multiple 
partners, condom use, douching, and smoking.
Implications
Prevention of preterm deliveries is of utmost 
importance throughout the world because it will help to 
save the lives of preterm neonates, improve the health of 
many children, and save millions of dollars. Numerous 
studies have shown that BV increases the incidence of 
premature rupture of membranes, preterm labor, 
chorioamnionitis, and postpartum endometritis. Early 
identification and optimal treatment of BV in pregnancy 
will certainly contribute to the worldwide goals listed 
above.
Nurse practitioners are frequently the ones providing 
care to obstetrical patients. Since they often make 
decisions on whether to treat BV and which medication to 
use if drug treatment is selected. They have the ability 
to have a positive influence on the preterm delivery rate. 
Most practitioners would elect to prescribe the optimal 
drug in the treatment of BV in pregnancy. Results of this 
study show little difference in recurrence rates of the
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three drugs used. Therefore, decisions about which drug to 
use in the treatment of BV in pregnancy must be 
individualized. A patient who appears hesitant to use oral 
medications might only accept treatment via vaginal route 
to reduce perceived drug exposure to the fetus. Vaginal 
metronidazole would be the choice for her. Cost of the 
medication is also a factor. Generic oral metronidazole 
averages $12.09 in the local area whereas vaginal 
metronidazole costs $35.97 and oral clindamycin costs 
$28.49. A woman's inability to pay for a more expensive 
prescription could lead to lack of treatment and increased 
risk of preterm labor, premature rupture of membranes, 
chorioamnionitis, and endometritis. Many of the reported 
side effects are similar for all three drugs such as 
gastrointestinal upset, nausea, vomiting, and abdominal 
cramps. The use of oral or vaginal metronidazole can also 
cause a metallic taste and vaginal candidiasis. And, 
clindamycin has been associated with pseudomembranous 
colitis (2% to 10%).
Recommendations 
Because BV has been associated with increased risk of 
preterm labor and premature rupture of membranes, further 
studies on a larger scale are needed to evaluate the 
effectiveness of drug treatments used in pregnancy. 
Additional research is needed on BV risk factors such as 
low income, unmarried, and Black race. Research should
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continue to evaluate the risks and benefits of medications 
to the mother and fetus. More focus needs to be placed on 
prevention of preterm labor and premature rupture of 
membranes rather than treatment of preterm labor once it 
occurs. We need to increase our understanding of BV and 
its relationship to pregnancy, preterm labor, and premature 
rupture of membranes.
Finally, we, as nurse practitioners, must remember our 
training on health promotion and wellness. Educate the 
woman on risk factors for BV such as frequent change of 
partners, frequent intercourse, condoms, smoking, and 
douching. Help her to keep the 'rings" of her Neuman 
System's Model strong to maintain optimal health and 
wellness. The following are case reviews showing how to 
maintain a strong Neuman Model.
Patient A is a 28 year old Black female who is 15 weeks 
pregnant at the time of her initial physical. The NP has 
diagnosed BV through the routine vaginal culture. Upon 
interviewing the patient, it was discovered she douched 
once or twice a week with plain water or a mixture of 
vinegar and water. Frequent douching is a culturally 
encouraged practice among Black women in this area. After 
treatment with oral metronidazole and education on perineal 
hygiene the infection resolved for the remainder of her 
pregnancy. This case involved primary, secondary, and 
tertiary interventions which strengthened Patient A's line
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of defense.
Patient B is a 16 year old White female who is 16 weeks 
pregnant. She also had a diagnosis of BV at her first 
office visit. Upon interviewing the patient, she reveals a 
recent change of partners with the occasional use of an 
unknown type of condom. Due to questionable compliance, a 
one dose oral metronidazole treatment was given. Education 
included increasing her awareness of increased BV with 
partner change and possibly the use of a new type of 
condom. Counseling on sexually transmitted diseases was 
also discussed. Treatment and education strengthened the 
primary, secondary, and tertiary lines of resistence. The 
return to a normal vaginal ecosystem strengthened the 
normal line of defense. Decreasing the patients risk 
factors (frequent partners and change in type of condom) 
strengthened the flexible line of defense. Patient B had 
no further episodes of BV during her pregnancy and 
delivered at 39 weeks gestation.
The selection of which researched drug to use makes 
little difference in the efficacy rate in treating BV. 
Education and health promotion consistent with Neuman^s 
beliefs would serve a more valuable service. Helping the 
pregnant woman to understand her risk factors and the 
importance of taking her medications as directed by her 
health care provider, when appropriate, will help to keep 
her lines of defense and lines of resistence strong to
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protect her inner core.
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Appendix B 
Human Research Committee Approval
G r a n d X â l u e y
SXf^TEU NIVERSrrY
I CAMPUS DRIVE • ALLENDALE. MICHIGAN 49401-9403 • 616/895-6611
January 19, 1999
Karen Taylor 
16661 SE 102 CTRd. 
Summerfield, FL 32691
Dear Karen:
Your proposed project entitled "Does the Method o f Treating Bacterial Vaginosis in 
Early Pregnancy Affect the Reoccurrence Rate Near Term?" has been reviewed. It 
has been approved as a study which is exempt jfrom the regulations by section 46.101 
o f the Federal Register 46( 16T-8336. January 26, 1981.
Sincerely,
Paul Huizenga, Chair
Human Research Review Committee
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Appendix C 
BV Log Sheet
Patienr #
Age
Parity
Insurance
Gest/l"
culture
Culture
results
PO
Metronidazole
Vag.
Metronidazole
PO Clindamycin
Recurrence
<35wks
Delivery < 
37wk
Culture
35-37wks
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